E3 Breast Cancer Taxotere Combination
To assess the efficacy of ZD6474 in combination with docetaxel in the treatment of ABC using the progression event count methodology
Advanced Breast Cancer
DRUG: Vandetanib (ZD6474)|DRUG: Docetaxel
Number of Patients With a Disease Progression Event, Number of patients with objective disease progression or death (by any cause in the absence of objective progression), RECIST tumour assessments carried out at screening (within 3 weeks before the 1st dose) and then as per site clinical practice until objective progression. The only additional mandatory RECIST assessment is at the point of data cut-off
To assess the efficacy of ZD6474 in combination with docetaxel in the treatment of ABC using the progression event count methodology